Related Experiment Videos
Antimutagenic effects in humans
1Biomedical Sciences Division, University of California, Lawrence Livermore National Laboratory 94550.
Abstract:
The application of antimutagenicity studies to human somatic mutation is discussed, with emphasis on the potential for future studies. Five assay-gene combinations are now available for measuring human somatic mutation in lymphocytes and erythrocytes. Results with these combinations have defined the human background levels, and show clear responses of mutant frequency to a variety of mutagens. The testing of antimutagenic effects on background frequencies is feasible, but has not yet been done. The major uncertainty in such studies is the unknown age of mutant cells in the background, since only the newly forming mutants are potentially susceptible to most antimutagenic treatments. Intervention studies in the face of active mutagenicity and the use of other genotoxicity endpoints, such as chromosome aberrations, micronuclei and DNA adducts, are considered briefly.
Insights
Antimutagenicity studies can now assess human somatic mutation using established assays. Future research should explore interventions targeting newly formed mutations to reduce cancer risk.
Area of Science:
- Human toxicology
- Somatic mutation research
- Antimutagenesis
Background:
- Human somatic mutation can be measured in lymphocytes and erythrocytes using five assay-gene combinations.
- Established methods define background mutation levels and mutagenic responses.
Purpose of the Study:
- To discuss the application of antimutagenicity studies to human somatic mutation.
- To highlight the potential for future research in this area.
Main Methods:
- Utilizing five assay-gene combinations for measuring human somatic mutation.
- Defining human background mutation levels and responses to mutagens.
Main Results:
- Established background levels for human somatic mutation.
- Demonstrated clear responses of mutant frequency to various mutagens.
Conclusions:
- Antimutagenicity testing on background mutation frequencies is feasible but not yet performed.
- A key challenge is the unknown age of mutant cells, as only newly formed mutants are susceptible to antimutagenic treatments.
- Future studies should consider intervention strategies for active mutagenicity and other genotoxicity endpoints.